Tokyo, Japan

Yohichi Shimazaki

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 1994-1996.


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1994-1996

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: **Inventor Yohichi Shimazaki: Innovating Pharmaceuticals in Tokyo**

Introduction

Yohichi Shimazaki is a notable inventor based in Tokyo, Japan, who has made significant contributions to the field of pharmaceuticals. With a total of three patents to his name, he is recognized for his innovative approaches to developing new compounds that hold potential therapeutic benefits.

Latest Patents

Shimazaki's latest patents include the following innovative compounds: 5-aminoacetylaminosulfonanilide compounds and 5-amino-2-phenoxysulfonanilide compound. These inventions showcase his expertise in synthesizing complex chemical structures aimed at enhancing medical treatments.

Career Highlights

Yohichi Shimazaki works at Taisho Pharmaceutical Co., Ltd., a reputable company known for its commitment to health and wellness through pharmaceutical innovations. His position allows him to engage with groundbreaking research and development initiatives that impact the industry positively.

Collaborations

Throughout his career, Shimazaki has collaborated with talented coworkers, including Kensei Yoshikawa and Mariko Kashiwa. These collaborations contribute to a dynamic environment that fosters creativity and inventiveness, essential for pioneering developments in pharmaceuticals.

Conclusion

In conclusion, Yohichi Shimazaki stands out as an influential inventor within the pharmaceutical sector in Tokyo. His dedication to innovation, as demonstrated by his patents and collaborations, underscores his commitment to advancing medical solutions that benefit society.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…